AGENT III: 12 week results 415 patients with CCS Class 2-4 angina not in need of urgent revascularization Ad5FGF-4 gene Adenoviral intracoronary infusion of human angiogenic fibroblast growth factor-4 (FGF-4) Placebo Low-dose High-dose Primary Endpoint: Exercise tolerance test time compared with baseline at 12 weeks, 6 months and 1 year. Secondary Endpoints: Time to number of patients with coronary events and death at 12 months Time to ST depression, angina, and quality of life parameters Presented at TCT 2004

AGENT III Trial: 12 week results Mean change in exercise duration from baseline to 12 weeks p=ns The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline seconds TCT 2004

AGENT III: 12-week results 415 people with stable angina were randomized to receive placebo or a low- or high-dose intracoronary infusion of an adenoviral gene for fibroblast growth factor-4 (FGF-4) before the trial was stopped earlier this year by the data safety and monitoring board The 12-week results show no difference between the three groups in the primary endpoint – mean change in exercise duration from baseline. TCT 2004